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Abstract
Retinoic acid (RA) regulates numerous aspects of central nervous system function through modulation of gene transcription via
retinoic acid receptors (RARs). However, RA has important roles independent of gene transcription (non-genomic actions) and in
the brain a crucial regulator of homeostatic plasticity is RAR control of glutamate receptor subunit 1 (GluR1) translation. An
assay to quantify RAR regulation of GluR1 translation would be beneficial both to study the molecular components regulating
this system and screen drugs that influence this critical mechanism for learning and memory in the brain. A bioluminescence
reporter assay was developed that expresses firefly luciferase under the control of the GluR1 5′ untranslated region bound by
RAR. This assay was introduced into SH-SY5Y cells and used to demonstrate the role of RARα in RA regulation of GluR1
translation. A screen of synthetic RAR and RXR ligands indicated that only a subset of these ligands activated GluR1 translation.
The results demonstrate the practicality of this assay to explore the contribution of RARα to this pathway and that the capacity of
RAR ligands to activate translation is a quality restricted to a limited number of compounds, with implications for their RAR
selectivity and potentially their specificity in drug use.
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Introduction
Nuclear receptors are involved in a major set of signalling
pathways in the brain, and crucial among these is the retinoic
acid receptor (RAR) family [1]. They have a well described
mechanism of action to regulate gene expression [2]. In addi-
tion, Bnon-genomic^ roles have been described for these re-
ceptors and a vital action for retinoic acid receptor alpha
(RARα) in the brain is regulation of mRNA translation during
homeostatic synaptic plasticity [3].
Synaptic connections in the brain are highly plastic. The
number and strength of synapses in neural pathways can be
modified in response to different factors such as experience
and this is an important element in the formation of memory.
With changes in synaptic strength, however, it is important to
maintain the stability of neural networks in order to prevent
the neural circuits from becoming hyper- or hypo-active [4, 5].
The ability of neurons to adjust their activity levels and main-
tain a balance between the relative strength of individual syn-
apses is called homeostatic synaptic plasticity [6, 7].
Homeostatic synaptic plasticity adjusts total synaptic strength
through different mechanisms such as regulating the release
and/or reuptake of presynaptic transmitters and changing the
number and/or sensitivity of postsynaptic receptors in order to
maintain a balance [8, 9]. For example, pharmacological ma-
nipulation studies have shown that an increase in synaptic
strength is induced when neural activity is inhibited by tetro-
dotoxin (TTX; which blocks sodium-gated voltage channels)
and an N-methyl-D-aspartate receptor (NMDA) receptor an-
tagonist [10, 11]. This synaptic increase in neural activity is
mediated by an increase in local translation and insertion of
the glutamate receptor 1 (GluR1, also known as GRIA1 and
GluA1) subunits of the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor [12–14]. AMPA
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receptors are glutamate excitatory transmembrane receptors
that mediate most of the neuroexcitatory synaptic transmission
in the central nervous system. AMPA receptors are composed
of four subunits (GluR1-GluR4), and they mediate
neuroplasticity and play an important role in cognition, mem-
ory and learning [15].
Retinoic acid (RA) is synthesised in neurons in response to
a decrease in neural activity. Aoto and colleagues demonstrat-
ed that the application of RA to hippocampal cultures in-
creased the amplitude of spontaneous excitatory postsynaptic
currents and that activity blockade induced RA synthesis in
the neurons [16–18]. The synthesised RA mediated a type of
homeostatic plasticity by regulating the translation of the
GluR1 subunit of the AMPA receptor in postsynaptic mem-
branes [3]. It does this through a cytoplasmically localised
population of the nuclear receptor RARα [16]. In the absence
of RA, the F-domain of RARα binds directly to consensus
sequences in the 5′ untranslated region (5′ UTR) of GluR1
mRNA; this is thought to inhibit the scanning mechanism,
whereby the 43S pre-initiation complex searches for the initi-
ation codon to start translation. During synaptic scaling,
blockade of synaptic activity triggers RA synthesis and the
RA binds to RARα. The ligand binding domain of RARα
undergoes a conformational change shifting position of helix
12, and it is proposed also the adjacent F-domain [3], resulting
in the weakening of the affinity for mRNA; and so the GluR1
mRNA is released allowing it to be translated. This causes an
increase in the postsynaptic AMPA receptor levels [3, 16].
In the current study, we wanted to design a simple quanti-
tative system that detects the effects of RA analogues on post-
transcriptional gene regulation in neurons during synaptic
scaling, in order to study factors that can promote or inhibit
this regulatory system. A bioluminescence reporter plasmid
that expresses firefly luciferase under the control of the
GluR1 5′ UTR region was produced and introduced into
SH-SY5Y neuroblastoma cells, a cell line commonly used
as a model of neuronal differentiation and function [19].
RARα was either overexpressed or knocked down in these
cells to demonstrate its involvement in RA control of GluR1
translation. Synthetic retinoids were then tested in this assay
for their ability to regulate AMPA receptor translation. We
demonstrate the utility of this system for screening RAR li-
gands for their therapeutic capacity to promote neuroplasticity
and for elucidating the molecular components that regulate
this form of translational regulation.
Materials and Methods
Retinoids
All-trans RA (ATRA) was purchased from Sigma-Aldrich.
HX600 and DA124 were a gift from Dr. Kagechika (Tokyo).
Synthetic retinoids and some non-retinoid homologues were
designed and prepared by the Whiting group (Durham
University) as described previously [20–24]. The molecular
structure of the RAR and RXR ligands used is shown in
Fig. 1.
Construction of Plasmids for GluR1 Assay
Firefly luciferase GluR1 reporter plasmid pTK1 was built
from a pGL3 (R2.1) vector (Promega) derivative that ex-
presses luciferase destabilised by addition of a PEST motif
under the control of a simian virus 40 (SV40) early promoter
and is referred to here as pGL3 (R2.1) promoter.
To generate pTK1, a 309-bp 5′ UTR fragment of the rat
GluR1 gene was generated by PCR from genomic DNA pre-
pared from rat HCN-A94 neural stem cells, using the
Expand™ High Fidelity PCR System kit (Sigma-Aldrich)
and primers AGGAGAGCAGAGGGAGAGG and
CAAAGATGTACGGCATATTCCTT. Fifteen base-pair ex-
tensions homologous to the vector ends were added by PCR
using nested primers CTTTTGCAAAAAGCTTGCTC
GGCTCCCCTTCC and TTGGCGTCTTCCATGGAGAT
TTGGTCTTCCCTCCCC. The resulting PCR products were
then inserted into HindIII/NcoI cut pGL3 (R2.1) promoter
vector using the In-Fusion® HD Cloning Kit (Clontech) to
generate GluR1 recombinant plasmid pTK1 containing the
rat GluR1 5′ UTR. The sequence was confirmed by Sanger
sequencing performed at the Dundee University DNA se-
quencing service.
CRISPR/CAS9 Plasmid Construction for Knockout
of RARα
The Gibson Designer tool at the Wellcome Trust Sanger
Institute Genome Editing database (WGE) [25] was used to
identify exon 7 as a target for disruption of the human RARα
open reading frame (ORF). Exon 7 was chosen because it is
present in all transcripts, and removing it causes frameshift
mutations leading to premature termination codons that make
the RNA subject to nonsense-mediated decay. Guide se-
quences in RARα exon 7 were identified using the CRISPR
Finder tool in WGE. Oligonucleotides CACGCGGT
ACACGCCCGAGC and GCTCGGGCGTGTACCGCGTG
were annealed in CutSmart® Buffer (NEB) and cloned into
the BbsI cut pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid
(Addgene 42,230) using Instant Sticky-end Ligase Master
Mix (NEB) to produce pTK3.
A homologous direct repair (HDR) donor plasmid was pre-
pared in order to introduce a puromycin cassette to repair the
DNA double-strand break generated by Cas9 nuclease in
RARα exon 7. The plasmid contains a puromycin selection
marker flanked by 1253 and 1313 base pairs of genomic DNA
from upstream and downstream of RARα exon 7. These
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fragments were amplified from genomic SH-SY5Y DNA
using primers CATGTGAGGCAAGAGATAAGTCAAC
and CTGAACCCGAACCCACTCTGAG, and TCTGTTAG
GTATCTCTAGAGGGCAG and GCATCTTTCTTGGG
ATTCAGTTCTT, respectively, using Phusion® High-
Fidelity DNA Polymerase (NEB). Further PCR reactions were
then carried out to add extension to the 5′ and 3′ flanks of the
PCR products that were homologous to the vector ends using
primers AAACGACGGCCAGTGAATTCCATGTG
AGGCAAGAGATAAGTCAAC and GCCGTTTGGTTCGA
AGTTCCCTGAACCCGAACCCACTCTGAG, and
TATCATGTCTGGATCCGGGGTCTGTTAGGTATCTCTAG
AGGGCAG and CCATGATTACGCCAAGCTTGATGCAT
CTTTCTTGGGATTCAGTTCTT, respectively. The puromycin
cassette was amplified from SERP_100_puc19_GIBSON_
EF1a_PURO plasmid (a gift from Dr. Bill Skarnes, Wellcome
Trust Sanger Institute) using primers GGAACTTCGAACCA
AACGGC and CCCCGGATCCAGACATGATA. The plasmid
backbone was obtained by digesting SERP_100_
puc19_GIBSON_EF1a_ PURO plasmid with EcoRI/ HindIII
enzymes. The four overlapping DNA fragments were joined
together to produce pTK4 using the Gibson Assembly®
Cloning Kit (NEB) according to the manufacturer’s
recommendations.
Cell Lines and Cell Culture Conditions
SH-SY5Y cells [26] were grown in T-75 culture flasks in
DMEM (Thermo Fisher Scientific) containing 10% FCS
(Thermo Fisher Scientific) and at 5% CO2/37 °C. SH-SY5Y
cells (SH-SY5YRARα) in which human RARα cDNA was
conditionally over-expressed in response to tetracycline were
supplied by Dr. Danielle Lindley [27]. These cells had been
prepared by stable transfection of human RARα2 cDNA
Fig. 1 Synthetic retinoids used for screening
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(Mammalian Gene Collection) into SH-SY5Ytet12 cells (pa-
rental SH-SY5Y cells transfected with the pcDNA6/TR tet
repressor plasmid [28]) and clonally-selected using methods
described by Goranov et al. [29]. SH-SY5YRARα cells were
cultured in T-75 culture flasks in DMEM containing 10%
FCS, 5 μg/ml blasticidin (Invitrogen) and 250 μg/ml zeocin
(Invitrogen) antibiotics to maintain selection of the tet repres-
sor and RARα plasmid constructs respectively. For all cell
cultures, the medium was changed three times a week, and
the cells were passaged at about 70% confluence using 0.05%
trypsin-EDTA solution. The passage number used for each
experiment was no higher than 30.
Preparation of RARα± Hemizygous Knockout SH-SY5Y
Line
SH-SY5Y cells were plated in 6-well plates at a density of
1.2 × 106 cells per well in 1-ml media and left to attach over-
night in DMEM medium containing 10% FCS. Cells were
then transfected with 1.5 μg of pTK3 and pTK4 plasmids each
using jetPRIME® transfection reagent (Polyplus-transfection
SA) according to the manufacturer’s recommendation. Cells
were then incubated for 4 h in a 5% CO2/37 °C incubator
before exchanging with normal DMEM containing 10%
FCS without puromycin antibiotic. The next day, the medium
was replaced with DMEM with 10% FCS and containing
2.5 μg/ml puromycin for selection. The medium was changed
every 3 days for a 10-day period.
Single SH-SY5Y colonies were picked and grown to
confluency in wells of a 24-well plate containing 500 μl of
DMEMwith 10% FCS and 2.5 μg/ml puromycin. The cells in
each well were then split and some of them were used for
DNA analysis while the rest were grown for cryopreservation.
DNAwas extracted from SH-SY5Y cells using an ISOLATE
genomic DNA mini Kit (Bioline) according to the manufac-
turer’s instructions. PCR reactions were carried out to confirm
RARα gene disruption using a GoTaq G2 polymerase
(Promega) to analyse the RARα gene using five different
pairs of primers.
The location of primer pairs used to characterise the knock-
out cell lines is shown in Fig. 2. Primer pair 1 (TGCACCAC
CATCCCCTCTCT and CGAGGTGGGAAGATCAATAC
TGCT) binds upstream and downstream of the region used
for gene disruption (exon 7 deletion) and normally produces a
2.9-kbp product. Insertion of the puromycin cassette increases
the length of this amplicon to 5.4 kbp. Primer pairs 2
(TGCACCACCATCCCCTCTCT and CCGAAGCC
AGCGTTGTG) and 4 (TCAGCGCCATCTGCCTCAT and
CGAGGTGGGAAGATCAATACTGCT) both detect the
presence of exon 7, and both produce amplicons of 1.4 kbp.
Insertion of the puromycin cassette at this locus is detected by
primer pairs 3 (TGCACCACCATCCCCTCTCT and
GCATGCTCTTCTCCACCTCAGT) and 5 (CTTCACCG
TCACCGCCG and CGAGGTGGGAAGATCAATAC
TGCT) and they produce amplicons of 1.5 kbp and 1.8 kbp,
respectively.
GluR1 Translation Assay
SH-SY5Y cells were seeded in 24-well plates at a density of
20,000 cells per well in 500 μl DMEM containing 10% FCS
without antibiotics. SH-SY5Y cells were then transfected with
one of the recombinant reporter plasmids pTK1 using
jetPRIME® transfection reagent. In parallel, cells were
transfected with two control plasmids pGL3 (R2.1) promoter
and the pGL3-Basic plasmid (Promega, GenBank U47295)
without promoter. In addition, each recombinant/control plas-
mid was co-transfected with a plasmid expressing Renilla lu-
ciferase (pRL-TK; Promega; GenBank AF025846.2) used as
an internal transfection control. The transfection mixtures
were prepared using 600 ng of recombinant/control firefly
plasmid and 150 ng of Renilla luciferase plasmid pRL-TK
and added to cells according to the manufacturer’s
recommendation,
Twenty-four hour after transfection, the medium was re-
placed with normal culture medium containing the test reti-
noid or DMSO alone as a standard. Retinoid dilutions were
prepared in DMEM with 10% FCS from stock solutions in
DMSO. Each retinoid was tested in triplicate at 10 μM con-
centration with a final DMSO concentration of 0.1%. In the
case of SH-SY5YRARα cells, the cells were also treated with
doxycycline (Melford) at a concentration of 1 μg/ml along
with the retinoids to drive RARα overexpression.
Dual Luciferase Assay
Firefly and Renilla luciferases were measured sequentially
using the Dual-Luciferase reporter assay system (Promega)
according to the manufacturer’s protocol. After 24 h of reti-
noid treatment, the medium was removed and the cells were
washed with 250 μl of PBS; 100 μl of passive lysis buffer was
then added to each well, and the plates incubated on a plate
shaker at room temperature for 15 min. Cell lysates
(10 μl) were transferred into wells of a 96-well white
luminometer plate (Greiner Bio-One), and the luciferase
assays were performed using a GloMax® 96 Microplate
Luminometer (Promega) according to the manufacturer’s
protocol.
Protein Analysis and Western Blotting
Cells were washed with cold PBS and lysed with 150 mM
NaCl, 1% Triton, 0.1% SDS, 50 mM HEPES containing pro-
tease inhibitor cocktail (Sigma) in double-distilled water.
Protein concentrations were measured using a BCA assay kit
(Thermo Fisher Scientific). Fifty micrograms of protein was
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loaded and separated by electrophoresis through 12% SDS-
polyacrylamide gels and transferred to nitrocellulose mem-
branes. Rabbit anti-RARα primary antibody (Santa cruz, sc-
551) along with horseradish peroxidase-conjugated secondary
anti rabbit IgG antibody (Jackson Immunoresearch) and
anti-β-actin peroxidase mouse primary antibody (Sigma,
A3854) were used in the study. Western blots were developed
using enhanced chemiluminescence (Millipore), and the pro-
tein bands were detected and scanned using a myECL Imager
(ThermoScientific).
Statistical Analysis
All data are presented as mean ± SEM of three independent
experiments. Statistical analyses were performed in Microsoft
Office Excel 2017, GraphPad Prism 7.0c version (Prism,
GraphPad Software, San Diego, CA) or R version 3.3.1 (R
Core Team, Vienna, Austria: The R Foundation for Statistical
Computing). The data were analysed by Student’s t test, one-
way ANOVAwith Newman-Keuls multiple comparison test,
or linear models with RARα expression level as an ordered
a
b
c
Fig. 2 Analysis of RARα gene disruption. a Schematic drawing of the
RARα wild type gene structure showing the region between exon 6 and
exon 8. b RARα gene structure after CISPR-Cas9-mediated replacement
of exon 7 by the puromycin expression cassette. The diagnostic PCR
amplicons produced using different pairs of primers are shown. Primer
pairs 2 and 4 are specific for the wild type RARα gene while primer pairs
3 and 5 detect the insertion of the puromycin expression cassette. Primer
pair 1 spans the region containing exon 7 and produces a longer product
when the puromycin expression cassette has been inserted. c
Characterisation of a hemizygous RARα± cell line. Genomic DNA
isolated from a clonal SH-SY5Y cell line was analysed using the primer
combinations described above, and amplicons were analysed by 1%
agarose gel electrophoresis. Both puromycin cassette and exon 7 were
detected in the clonal SH-SY5Y cells which indicate that only one copy
of RARα was knocked out. M is a DNA size standard
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factor, as appropriate; a p value < 0.05 was considered statis-
tically significant. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001.
Results
A Dual Luciferase Assay for Detecting RARα-Ligand
Regulation of GluR1 Translation
To quantify RARα ligand regulation of GluR1 translation, a
highly sensitive bioluminescence reporter composed of firefly
luciferase under the control of the GluR1 5′ UTR was
employed. The rat GluR1 5′UTR sequence was chosen based
on previous work by Poon and Chen who identified consensus
RNA binding motifs in the 5′ UTR regions of rat GluR1
mRNA that preferentially bind RARα for translational control
[3]. This region including the RARα binding motifs is con-
served in the human GluR1 5′ UTR (Fig. 3a). Based on that, a
firefly luciferase GluR1 reporter plasmid, designated pTK1,
was designed by cloning a fragment of the 5′UTR region (that
contains consensusmotifs) from rat GluR1 into a pGL3 (R2.1)
under control of the SV40 promoter. Figure 3 b shows the
sequence of the relevant regions of pTK1 construct.
The construct was transfected into SH-SY5Y cells, a fre-
quently used model of neuronal cells, employing a SH-
SY5YRARα variant in which high levels of RARα expression
can be induced with tetracycline or the more stable derivative
doxycycline [30]. SH-SY5YRARα cells were transfected with
the rat GluR1 reporter pTK1, or a pGL3 (R2.1) promoter
parental plasmid lacking the insert to demonstrate that the
response is due to the sequence inserted. In addition, the
pGL3-Basic plasmid, lacking a promoter but containing a
normal firefly luciferase gene without the destabilising
PEST sequence present in the pGL3 (R2.1) derivatives, was
used as a sensitive control for promoter and GluR1 5′ UTR-
independent effects of RARα on luciferase expression. For all
assays, cells were co-transfected with pRL-TK expressing
Renilla luciferase as reference and independent measure of
transfection efficiency. Transfected cells were treated with
10-μM ATRA for 24 h, and then luciferase activities were
measured (Fig. 4). Ten μM ATRAwas used because in many
studies SH-SY5Y cells are treated with this concentration of
ATRA in order to study its action [31–34].
In a first experiment, the effect of ATRA on reporter gene
expression was analysed in SH-SY5YRARα cells grown in the
absence of doxycycline, and so without RARα overexpres-
sion (Fig. 4a). Firefly and Renilla luciferase activities were
measured separately, and for comparison, firefly luciferase
activity was normalised with respect to Renilla luciferase ac-
tivity and standardised with respect to activity in cells not
treated with ATRA. In the case of the two controls, pGL3-
Basic and pGL2 (R2.1) promoter, luciferase activity did not
significantly differ between cells treated with/without ATRA.
On the other hand, cells transfected with pTK1 containing the
rat GluR1 5′ UTR showed an approximately 1.6-fold increase
in luciferase expression when treated with ATRA. These re-
sults indicate that the reporter assay was, as expected, respon-
sive to RA.
The effect of RARα overexpression was tested by inducing
RARα expression with doxycycline. Overexpression of
RARα had no significant effect on the response to ATRA of
the different plasmids used as negative controls: only lucifer-
ase under the control of the rat GluR1 5′ UTR region was
increased by treatment with ATRA (Fig. 4b). However, given
that the response to ATRA was significantly less following
doxycycline-induced RARα over-expression (p = 0.0231),
routine assays were done without doxycycline-treatment of
SH-SY5YRARα cells.
The Luciferase Assay Is Sensitive to RARα Levels
Our assay models the effects of RARα in controlling transla-
tion of GluR1 mRNA. To test whether the response was
a
b
Fig. 3 Retinoic acid control of GluR1 translation. aAlignment of 5′UTR
sequences of human and GluR1 mRNA. The RARα consensus binding
sites identified previously by Poon and Chen using SELEX are
underlined and in bold. b Partial sequence of the pTK1 construct
showing the SV40 promotor shaded in yellow, the GluR1 5′ UTR
shaded in blue, and the beginning of the firefly luciferase open reading
frame in green. The RARα consensus binding sites are in red and
underlined, while vector sequence is unshaded
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sensitive to RARα levels, we directly compared the response
to ATRA in SH-SY5Y hemizygous RARα± knockout cells to
parental SH-SY5Y cells and SH-SY5YRARα cells overex-
pressing RARα after 1 μg doxycycline treatment. Analysis
by Western blotting demonstrated clear differences in RARα
protein levels in these three cell types (Fig. 5a), with a 2.5-fold
higher RARα level in the doxycycline-treated SH-SY5YRARα
cell line and a 2.1-fold lower RARα level in the hemizygous
RARα± SH-SY5Y cell line compared to the parental SH-
SY5Y cells.
The three different cell types were then transfected with
pTK1 and pRL-TK and treated with/without ATRA to deter-
mine the effects of RARα levels on the reporter assay
(Fig. 5b). There was a clear reduction in reporter activ-
ity (effect coefficient − 0.8) as RARα expression levels
increased (Linear model with RARα expression as an
ordered factor: p < 0.001; Fig. 5b), and ATRA treatment
had a clear effect in inducing a 2.3- to 2.6-fold increase
in reporter activity (Linear model, effect of RA,
p < 0.001). In addition, ATRA treatment had a signifi-
cant effect (Linear model, interaction term, p = 0.04) in
increasing the negative relationship between RARα ex-
pression levels and reporter activity. These results show
that the effect of RARα is dose-dependent, with the
lowest reporter activity in cells with the highest RARα
expression (Fig. 5b).
Having established that pTK1 containing the rat GluR1 5′
UTR region was, as expected, responsive to RA, we exploited
this to screen novel synthetic RAR and two commercially
available RXR ligands with differing capacity to induce
ligand-activated transcription (unpublished data), for their
ability to regulate GluR1 translation compared to ATRA.
TTNN, AH61, DC271, DC440 and DC444 are analogues of
ATRA that exhibit strong binding affinity for the RARs, while
DC303, DC324 and DC329 are non-active retinoid analogues
that were designed specifically to be longer structures than RA
and would therefore be unable to bind into the RAR ligand-
binding pocket [21, 35, 36]. HX600 [37] and DA124 [38] are
known to be RXR agonists that do not exhibit significant
binding affinity for the RARs. SH-SY5YRARα cells
cotransfected with pTK1 containing the rat GluR1 5′ UTR
region, and pRL-TK expressing Renilla luciferase were treat-
ed for 24 h with 10 μM retinoids, and for comparison with
10 μMATRA or with the solvent DMSO (Fig. 6). In addition
to ATRA, treatment with only four out of the tested RAR or
RXR ligands, namely TTNN, AH61, DC271 and DC440
caused a statistically significant increase in luciferase activity.
In addition, treatment with DC444 also increased luciferase
activity, but not significantly. DA124 and HX600 did not have
any effect on luciferase activity as expected because they are
RXR, and not RAR, ligands.
Discussion
A sensitive bioluminescence-based dual luciferase assay was
developed to enable the study of the translational control of
GluR1 mRNA by RARα. For this assay, the 5′UTR region of
a
b
Fig. 4 pTK1 containing the rat GluR1 5′ UTR region is sensitive to RA-
treatment of SH-SY5Y cells. SH-SY5YRARα cells were transfected with
the indicated plasmids and with pRL-TK expressing Renilla luciferase as
a reference. After transfection, cells were treated with 10-μM ATRA for
24 h before luciferase activities were measured. a The graph shows
standardised firefly luciferase activity in SH-SY5Y RARα cells grown in
the absence of doxycycline. Firefly luciferase activity was normalised
with respect to Renilla luciferase activity and then standardised with
respect to normalised luciferase activity in cells not treated with
ATRA (−ATRA), which was set at 1. b) Luciferase activity in SH-
SY5Y RARα cells treated with doxycycline. Shown are normalised,
standardised luciferase activities determined as described for a. Shown
are mean values of three biological replicates. Error bars indicate standard
error of the mean (SEM) (**p ≤ 0.01, ***p ≤ 0.001, Student’s t test)
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rat GluR1 gene was inserted upstream of the initiation codon
of a luciferase gene. Using this construct, together with pRL-
TK expressing Renilla luciferase as reference and in combi-
nation with SH-SY5Y cells with normal, elevated or reduced
RARα levels, the effect of RARα levels, and of synthetic
RAR/RXR ligands, could be quantified for their capacity to
regulate GluR1 translation by measuring changes in luciferase
activity.
Control of translation by RA via RARα is a non-genomic
activity, breaking the dogmatic view of the RARs as purely
transcriptional regulators restricted to the nucleus [3, 16, 39].
RARα is actively exported from the nucleus by a nuclear
export signal (NES) present in domain E (the ligand binding
domain) of the receptor [3, 40]. In the cytoplasm, RARα acts
as an RNA binding protein, binding directly to different
mRNAs such as dendritically localised GluR1 mRNA. The
C-terminal F-domain of RARα binds to specific sequences in
the 5′ UTR region of the rat GluR1 mRNA and represses the
translation of GluR1 [3]. This mechanism of inhibition may be
similar to the translational control of ferritin mRNA by iron
regulatory protein (IRP), which binds to the ferritin mRNA
and prevents the binding of the 43S pre-initiation complex to
it [41]. RA binding to RARα causes conformational changes
in the receptor which relieves the association between RARα
and GluR1 mRNA, resulting in GluR1 translation [3].
Schwertz and colleagues also showed that RARα can regulate
mRNA translation via interaction with the 3′UTR of genes, as
well as their 5′ UTR region [42]. They reported in human
platelets the presence of the RARα consensus binding sites
identified previously by Poon and Chen [3] in the 3′ UTR
region of microtubule associated protein 1 light chain 3 beta
2 (MAP1LC3B2) transcripts, the 3′ UTR and 5′ UTR regions
of SLAIN motif containing protein 2 (SLAIN2) and the 5′
UTR region of angiopoietin-1 (ANGPT1) [42]. Thus RA
can regulate translation of several proteins [42] but GluR1 is
the only regulated subunit presently described to be part of an
ionotropic receptor.
Notably, this study demonstrated that RARα is involved in
GluR1 translation as reported previously [3, 16, 39] by dem-
onstrating a negative dose-dependent effect of RARα on the
a
b
Fig. 5 RARα levels influence the pattern of inhibition of translation. a A
Western blot showing RARα levels in SH-SY5YRARα cells that
overexpress the receptor after 1-μg doxycycline treatment for 24 h, SH-
SY5Y cells and hemizygous RARα± SH-SY5Y cells. The graph shows
the ratio of RARα levels normalised to β-actin (ACTB) for all three cell
types. Shown are mean values of three biological replicates. Error bars
indicate standard error of the mean (SEM) (*p ≤ 0.05, one-way ANOVA
with Newman-Keuls multiple comparison test). b The three different SH-
SY5Y cell lines were transfected with pTK1 containing the rat GluR1 5′
UTR region and pRL-TK, and treated with/without 10-μMATRA. After
24 h, cells were lysed and luciferase activity was measured. The firefly
luciferase activity was normalised with respect to Renilla luciferase ac-
tivity. Shown are the average of normalised luciferase levels (firefly/
Renilla) of three biological replicates. Error bars indicate SEM. The data
were analysed using a linear model with ATRA treatment and RARα
expression (ordered factor) as explanatory variables (see text)
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GluR1 translation assay (Fig. 5). However, we could not con-
firm whether RARα is the only receptor regulating GluR1 in
response to RA, as we were unable to test cells lacking all
RARα genes.
An ATRA concentration of 10 μM was used in this assay.
Almost all studies treating SH-SY5Y cells with ATRA use a
high, 10 μM concentration, for example [31–34]. The most
effective concentration for inducing differentiation of SH-
SY5Y cells using ATRA is 10 μM concentration [43, 44],
which may be because ATRA rapidly induces strong expres-
sion of the catabolic enzymes CYP26A1 and CYP26B1 [45],
which counteract the effects of RA, thus necessitating high
concentrations.
A range of RAR ligands together with two known RXR
ligands were tested for their capacity to regulate GluR1 trans-
lation (Fig. 6). Of those tested, only four increased
GluR1 translation significantly, i.e. DC271, DC440,
TTNN and AH61 with DC271 and DC440 also being
stronger than ATRA, although not significantly. As ex-
pected, neither of the RXR ligands, DA124 nor HX600
increased GluR1 translation. Thus, it is the synthetic
retinoids that activate RARs, and not those that only
activate RXRs, which induce GluR1 translation. The
use of the dual luciferase GluR1 translation assay to
screen for bioactive compounds that promote GluR1
translation will identify routes by which homeostatic plasticity
in the brain may be promoted. This may be of application to
disorders such as fragile X syndrome in which homeostatic
plasticity is impaired which may contribute to the neural dys-
function in this disease [46].
In summary, a reporter gene system has been developed to
study the translational control of GluR1 by RA. The assay was
used to investigate the influence of levels of RARα expression
onGluR1 translation. This approach can be used to investigate
any protein that influences this pathway as proposed for frag-
ile X mental retardation protein (FMRP) [46]. Exploration of
the system may show a level of control parallel to the enor-
mous complexity of RAR regulated transcription and the
dozens of coregulators that contribute to this. This assay can
also be used to identify RARα ligands for their capacity to
increase GluR1 expression which will then increase AMPA
receptor levels and which may provide therapeutics that reg-
ulate homeostatic plasticity in the brain. The insights demon-
strated here could potentially be used to design RAR ligands
of greater specificity for RAR triggered pathways, allowing
the development of RAR-based therapeutics with fewer side
effects for disorders impacted on by neuroplasticity, such as
Alzheimer’s disease [47].
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Fig. 6 Identification of synthetic retinoids that act on the GluR1 5′ UTR
region. SH-SY5YRARα were transfected with pTK1 containing the rat
GluR1 5′ UTR region and with pRL-TK. After 24 h, they were treated
with 10 μM of retinoids. After a further 24 h, cells were lysed and
luciferase activities were measured as described. The graph shows
firefly luciferase activity normalised with respect to Renilla luciferase
activity, with activity in cells treated with DMSO only set at 1. Shown
are mean values of three biological replicates. Error bars indicate SEM
(*p ≤ 0.05; **p ≤ 0.01, one-way ANOVA with Newman-Keuls multiple
comparison test)
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